Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the pulmonary fibrosis in microscopic polyangiitis with anti-myeloperoxidase antibodies and rheumatoid factor. Literature review and own observation

Depending on the epitope specificity of antineutrophil cytoplasmic antibodies (ANCA) and the presence or absence of a granulomatous inflammation. Patients with ANCA-associated vasculitis (AAV) show variability in clinical manifestations and prognosis depending on the epitope specificity of ANCA and the presence or absence of granulomatous inflammation. In this regard, it is important to identify the clinical and immunological phenotypes of AAV and a personalized approach to treatment. Microscopic polyangiitis (MPA) with antibodies to myeloperoxidase (aMPO) has a relatively high incidence of lung involvement and pulmonary fibrosis. We present our own clinical case of pulmonary fibrosis in MPA with aMPO and rheumatoid factor. Literature data are discussed. In cases of early arthritis and interstitial pneumonia, the possibility of AAV should be considered, a detailed examination is necessary to identify pathognomonic signs of AAV, including asymptomatic ones. Before prescribing immunosuppressants, the epitope specificity of ANCA should be determined. Treatment with rituximab, mycophenolate mofetil and nintedanib is discussed.

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1): 1-11. doi: 10.1002/art.37715

2. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452-3462. doi: 10.1002/art.34562

3. Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCAassociated vasculitis – Clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12(10):570-579. doi: 10.1038/nrrheum.2016.123

4. Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum. 2008;58(9):2908-2918. doi: 10.1002/art.23800

5. Beketova TV. Diagnostic algorithm for antineutrophil cytoplasmic antibody-associated systemic vasculitis. Terapevticheskii arkhiv. 2018;90(5):13-21 (In Russ.). doi: 10.26442/terarkh201890513-21

6. Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc. 1990;65(6):847-856. doi: 10.1016/s0025-6196(12)62575-0

7. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004;9(2):190-196. doi: 10.1111/j.1440-1843.2004.00581.x

8. Foulon G, Delaval P, Valeyre D, Wallaert B, Debray MP, Brauner M, et al. ANCA-associated lung fibrosis: Analysis of 17 patients. Respir Med. 2008;102(10):1392-1398. doi: 10.1016/j.rmed.2008.04.023

9. Nozu T, Kondo M, Suzuki K, Tamaoki J, Nagai A. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration. 2009;77(4):407-415. doi: 10.1159/000183754

10. Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, et al.; French Vasculitis Study Group. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009;68(3):404-407. doi: 10.1136/ard.2008.096131

11. Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J. 2010;36(1):116-121. doi: 10.1183/09031936.00110109

12. Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: A series of 49 patients and review of the literature. Medicine (Baltimore). 2014;93(24):340-349. doi: 10.1097/MD.0000000000000217

13. Huang H, Wang YX, Jiang CG, Liu J, Li J, Xu K, et al. A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China. BMC Pulm Med. 2014;14:8. doi: 10.1186/1471-2466-14-8

14. Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2(1):e000058. doi: 10.1136/bmjresp-2014-000058

15. Flores-Suárez LF, Ruiz N, Saldarriaga Rivera LM, Pensado L. Reduced survival in microscopic polyangiitis patients with pulmonary fibrosis in a respiratory referral centre. Clin Rheumatol. 2015;34(9):1653-1654. doi: 10.1007/s10067-015-2967-1

16. Watanabe T, Minezawa T, Hasegawa M, Goto Y, Okamura T, Sakakibara Y, et al. Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: A retrospective single-center study. BMC Pulm Med. 2019;19(1):194. doi: 10.1186/s12890-019-0969-5

17. Zakharova EV, Yakovlev VN, Vinogradova OV, Sheikh ZhV, Zhidkova NV, Alekseev VG. ANCA-associated vasculitis affecting lungs and kidneys: Clinical and morphological characteristic, treatment, outcomes. Clinical Medicine (Russian Journal). 2013;91(7):38-43 (In Russ.).

18. Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107(4):608-615. doi: 10.1016/j.rmed.2013.01.006

19. Alba MA, Flores-Suárez LF, Henderson AG, Xiao H, Hu P, Nachman PH, et al. Interstital lung disease in ANCA vasculitis. Autoimmun Rev. 2017;16(7):722-729. doi: 10.1016/j.autrev.2017.05.008

20. Moon JS, Lee DD, Park YB, Lee SW. Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor. Clin Rheum. 2018;37(10):2771-2779. doi: 10.1007/s10067-017-3902-4

21. Frolova NF, Korsakova LV, Stolyarevich ES, Nikonorova NO, Beketova TV. The onset of ANCA-associated systemic vasculitis masking rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(6):653-656 (In Russ.). doi: 10.14412/1995-4484-2015-633-656

22. Pagnoux C, Seror R, Bérezné A, Rouabhia S, Goulvestre C, Guillevin L. Remittent non-destructive polysynovitis in P-ANCApositive vasculitis patients with anti-CCP antibodies. Joint Bone Spine. 2010;77(6):604-607. doi: 10.1016/j.jbspin.2010.02.013

23. Kamali S, Polat NG, Kasapoglu E, Gul A, Ocal L, Aral O, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol. 2005;24(6):673-676. doi: 10.1007/s10067-005-1104-y

24. Watanabe S, Gono T, Nishina K, Sugitani N, Watanabe E, Yabe H, et al. Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibodyassociated vasculitis. BMC Immunol. 2017;18(1):53. doi: 10.1186/s12865-017-0234-8

25. Nathani D, Barnett MH, Spies J, Pollard J, Wang MX, Kiernan MC. Vasculitic neuropathy: Comparison of clinical predictors with histopathological outcome. Muscle Nerve. 2019;59(6):643-649. doi: 10.1002/mus.26431

26. Martín-Nares E, Zuñiga-Tamayo D, Hinojosa-Azaola A. Prevalence of overlap of antineutrophil cytoplasmic antibody associated vasculitis with systemic autoimmune diseases: An unrecognized example of poliautoimmunity. Clin Rheumatol. 2019;38(1):97-106. doi: 10.1007/s10067-018-4212-1

27. Kısacık B, Önder ME, Sayarlıoğlu M, Onat AM. Symmetric polyarthritis as an initial symptom in granulomatosis with polyangiitis: A report of six cases and review of the literature. Eur J Rheum. 2018;5(3):191-193. doi: 10.5152/eurjrheum.2018.17050

28. Holle JU, Herrmann K, Gross WL, Csernok E. Comparative analy sis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin Exp Rheumatol. 2012;30(1 Suppl 70):66-69.

29. Kallenberg CG. Key advances in the clinical approach to ANCAassociated vasculitis. Nat Rev Rheumatol. 2014;10(8):484-493. doi: 10.1038/nrrheum.2014.104

30. Braun MG, Csernok E, Schmitt WH, Gross WL. Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. J Rheumatol. 1996;23(5):826-830.

31. Cambridge G, Williams M, Leaker B, Corbett M, Smith CR. Antimyeloperoxidase antibodies in patients with rheumatoid arthritis: Prevalence, clinical correlates, and IgG subclass. Ann Rheum Dis. 1994;53(1):24-29. doi: 10.1136/ard.53.1.24

32. Al-Rubaye M. Anti-neutrophlic cytoplasmic antibody elastase, lactoferrin, cathapsin G, and lysozyme in a sample of Iraqi patients with rheumatoid arthritis. Journal of the Faculty of Medicine Baghdad. 2015;57(1):68-74. doi: 10.32007/jfacmedbagdad.571312

33. Locht H, Skogh T, Wiik A. Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis. Ann Rheum Dis. 2000;59(11):898-903. doi: 10.1136/ard.59.11.898

34. Beketova TV. Microscopic polyangiitis associated with antineutrophil cytoplasmic antibodies: Clinical features. Terapevticheskii arkhiv. 2015;(5):33-46 (In Russ.).

35. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: Clinical applications. Disease Markers. 2013;35(6):727-734. doi: 10.1155/2013/726598

36. van Schaardenburg D, Lagaay AM, Breedveld FC, Hijmans W, Vandenbroucke JP. Rheumatoid arthritis in a population of persons aged 85 years and over. Br J Rheumatol. 1993;32(2):104-109. doi: 10.1093/rheumatology/32.2.104

37. Shillitoe EJ, Lehner T, Lessof MH, Harrison DF. Immunological features of Wegener’s granulomatosis. Lancet. 1974;1(7852):281-284. doi: 10.1016/s0140-6736(74)92594-x

38. Schirmer JH, Wright MN, Vonthein R, Herrmann K, Nölle B, Both M, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford). 2016;55(1):71-79. doi: 10.1093/rheumatology/kev286

39. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in antineutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7(2):240-247. doi: 10.2215/CJN.05610611

40. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. doi: 10.1136/annrheumdis-2016-209133

41. Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.) doi: 10.14412/1995-4484-2019-3-40

42. Hoffmann-Vold AM, Maher TM, Philpot EP, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: Evidence-based European consensus statements. Lancet Rheumatol. 2020;2(2): 71-83. doi: 10.1016/S2665-9913(19)30144-4

43. Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428-436. doi: 10.1016/j.semarthrit.2014.09.002

44. Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353-359. doi: 10.1111/resp.12214

45. Lepri G, Avouac J, Airò P, Anguita Santos F, Bellando-Randone S, Blagojevic J, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016;34(Suppl 100(5)):181-185.

46. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al.; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7

47. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005-1008. doi: 10.1093/rheumatology/kei211

48. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-646. doi: 10.3899/jrheum.121043

49. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al.; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. doi: 10.1056/NEJMoa1908681

50. Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20(1):3. doi: 10.1186/s12890-019-1030-4

51. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al.; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. doi: 10.1056/NEJMoa1903076

52. Ananieva LP, Avdeev SN, Tyurin IЕ, Lila AМ, Zagrebneva AI, Maslyanskiy АL, et al. Chronic fibrosing interstitial lung disease with progressive phenotype. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(6):631-636 (In Russ.). doi: 10.47360/1995-4484-2020-631-636